8-K: Humana Reports Mixed Q1 Results, Revises Full Year EPS Guidance Amidst Industry Headwinds

Humana reported first quarter earnings that exceeded expectations but revised its full-year GAAP EPS guidance downwards while affirming its adjusted EPS outlook, citing challenges in the Medicare Advantage market.

Summary

• Humana's first quarter 2024 adjusted earnings per share (EPS) were $7.23, exceeding internal expectations and consensus estimates.
• The company's GAAP EPS for Q1 was $6.11, compared to $9.87 in the same period last year.
• Humana has revised its full-year 2024 GAAP EPS guidance to approximately $13.93, down from the previous estimate of approximately $14.87.
• The company reaffirmed its full-year 2024 adjusted EPS guidance of approximately $16.00.
• Humana raised its 2024 individual Medicare Advantage annual membership growth forecast by 50,000 to approximately 150,000, or 2.8 percent.
• The company's insurance segment benefit ratio for the full year 2024 is expected to be approximately 90 percent.
• Humana continues to expand its Medicaid platform with recent contract wins in Florida, Texas, and Virginia.
• The company's operating cash flow was $423 million, significantly lower than the $6.687 billion in the same quarter last year, primarily due to the timing of a CMS premium payment in the prior year.
• Humana repurchased 1,804,645 shares at an average price of $388.78 per share in Q1 2024.
• The company's debt-to-total capitalization ratio increased to 45.1 percent from 41.1 percent year-over-year.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the downward revision of GAAP EPS guidance and concerns about the 2025 outlook, despite positive aspects like membership growth and cost management. The company is facing significant headwinds in the Medicare Advantage market.

Positives

• First quarter adjusted EPS exceeded expectations due to lower administrative expenses.
• Individual Medicare Advantage membership growth is trending higher than previously anticipated.
• Humana is successfully expanding its Medicaid business with new contract wins.
• The company is actively repurchasing shares, indicating confidence in its long-term outlook.
• Humana's CenterWell primary care business is experiencing strong patient growth.
• The company is seeing improved patient retention in its primary care business.
• Humana is making progress in integrating its CenterWell assets, leading to increased member satisfaction and loyalty.

Negatives

• Full-year GAAP EPS guidance has been revised downwards.
• The company's operating cash flow declined significantly year-over-year.
• The debt-to-total capitalization ratio has increased.
• The company is facing headwinds in its CenterWell Primary Care Organization due to the v28 risk model revision.
• The 2025 final MA rate notice is expected to negatively impact benefit levels, plan stability and choice for seniors.
• The company no longer believes $6 to $10 of Adjusted EPS growth is the appropriate target range for 2025.
• The company anticipates significant impacts to benefits in the near term due to the current landscape.

Risks

• The final Medicare Advantage rate notice for 2025 is not sufficient to address the current medical cost trend environment.
• The company faces pricing limitations imposed by the Total Beneficiary Cost (TBC) change thresholds.
• There is uncertainty regarding the impact of the final rate notice and Policy and Technical Rule, as well as the Inflation Reduction Act (IRA).
• The company's 2025 Adjusted EPS growth outlook is subject to several variables, including competitor pricing actions and net membership growth.
• The Change Healthcare disruption is impacting claim submissions and requires a more conservative approach to quarter end reserving.
• The company is exposed to risks related to government contracts, regulatory changes, and legal actions.
• Humana faces competition in attracting and retaining talented employees.
• The company's pharmacy business is subject to regulations and supply chain risks.

Future Outlook

Humana expects benefit levels, plan stability and choice for seniors to be negatively impacted by the 2025 final MA rate notice, and no longer believes $6 to $10 of Adjusted EPS growth is the appropriate target range for 2025. The company will provide an update on its bid strategy post bid finalization, with a further update in the Fall once it has visibility into competitor plans and expected membership implications. Formal 2025 guidance will be provided on the fourth quarter earnings call early next year.

Management Comments

• Management stated that first quarter financial results exceeded internal expectations and consensus estimates.
• Management noted that the first quarter benefit ratio is in line with expectations, taking a more conservative approach to quarter end reserving due to the Change Healthcare disruption.
• Management highlighted the increase in full year 2024 individual MA membership growth guidance by 50,000 to 150,000.
• Management reaffirmed the 2024 Adjusted EPS outlook of approximately $16 and full year Insurance segment benefit ratio guidance of approximately 90 percent.
• Management expressed pride in the continued organic success expanding the Medicaid platform.
• Management stated that the 2025 final MA rate notice is not sufficient to address the current medical cost trend environment.
• Management believes the recovery process for margin recovery and profitable growth will be longer than previously anticipated.
• Management believes in the strong fundamentals and growth outlook of MA and expects that the industry will adjust to the current funding and regulatory environment.
• Management stated that Humana's platform, unique focus on MA, and expanding CenterWell capabilities will allow it to compete effectively and deliver compelling shareholder value over the long-term.

Industry Context

The announcement highlights the challenges faced by the Medicare Advantage industry due to changes in the regulatory and funding environment. The revised guidance and concerns about the 2025 rate notice reflect broader industry pressures related to medical cost trends and government reimbursement policies. Humana's focus on value-based care and its CenterWell assets aligns with industry trends towards integrated care delivery models.

Comparison to Industry Standards

• Humana's revised GAAP EPS guidance reflects a trend of reduced profitability in the Medicare Advantage sector, similar to challenges faced by competitors like UnitedHealth Group and CVS Health, who have also reported increased medical costs and lower margins in their MA businesses.
• The increase in Humana's debt-to-total capitalization ratio to 45.1% is higher than some of its peers, such as Elevance Health, which has maintained a more conservative capital structure.
• Humana's focus on expanding its Medicaid business is a strategic move to diversify its revenue streams, similar to other large health insurers who are also targeting growth in government-sponsored programs.
• The company's emphasis on value-based care and the integration of its CenterWell assets is in line with industry trends towards more coordinated and efficient healthcare delivery, comparable to initiatives by companies like Oak Street Health and ChenMed.
• Humana's Medicare Advantage membership growth of 150,000 is a positive sign, but it is important to compare this to the growth rates of competitors like UnitedHealth and Aetna to assess its relative performance in the market.

Stakeholder Impact

• Shareholders will be impacted by the revised GAAP EPS guidance and the uncertainty surrounding the 2025 outlook.
• Members may experience changes in benefit levels and plan stability due to the 2025 MA rate notice.
• Employees may be affected by the company's efforts to drive productivity and cost efficiencies.
• Providers may be impacted by changes in reimbursement models and the company's focus on value-based care.
• Customers may experience changes in plan options and pricing.

Next Steps

• Humana will finalize its pricing decisions for the 2025 MA bids by the first Monday in June.
• The company will provide an update on its bid strategy post bid finalization.
• Humana will provide a further update in the Fall once it has visibility into competitor plans and expected membership implications.
• The company will provide formal 2025 guidance on its fourth quarter earnings call early next year.

Key Dates

Keywords

Medicare Advantage, Medicaid, EPS, CenterWell, Healthcare, Insurance, Membership Growth, Benefit Ratio, Operating Cash Flow, Value-Based Care